Submitted:
26 August 2024
Posted:
26 August 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Population and Protocol
2.2. Echocardiographic Assessment
2.3. Statistics
3. Results
4. Discussion
5. Conclusions
6. Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020, 324, 259–269.
- Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020, 395, 1771–1778.
- Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020, 324, 294–296. [CrossRef]
- Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ. 2020, 369, m2094.
- Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020, 395, 1607–1608. [CrossRef]
- Belhadjer Z, Me´ot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context to global SARS-CoV-2 pandemic. Circulation. 2020, 142, 429–436.
- Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020, 383, 334–46. [CrossRef]
- World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: scientific Brief 2020. Available at: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. Accessed August 17, 2024.
- Centers for Disease Control and Prevention health alert network (HAN). Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Available at: https://archive.cdc.gov/#/details?url=https://emergency.cdc.gov/han/2020/han00432.asp. Accessed August 17, 2024.
- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long- term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017, 135, 927–999. [CrossRef]
- Kabeerdoss J, R Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2021, 41, 19–32.
- Rivas MN, Arditi M. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Common Inflammatory Pathways of Two Distinct Diseases. Rheum Dis Clin North Am. 2023, 49, 647–659.
- Godfred-Cato S, Abrams JY, Balachandran N, et al. Distinguishing multisystem inflammatory syndrome in children from COVID-19, Kawasaki Disease and toxic shock syndrome. Pediatr Infect Dis J. 2022, 41, 315–323. [CrossRef]
- Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021, 17, 731–748. [CrossRef]
- Haslak F, Gunalp A, Kasapcopur O. A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children. Curr Opin Rheumatol. 2023, 35, 6–16. [CrossRef]
- Bashir A, Bhat AA, Jan M, Wani KA. Kawasaki like illness in COVID versus Kawasaki disease in pre-COVID era. Int J Contemp Pediatr. 2023, 10, 484–487. [CrossRef]
- Phi DL, Dao TL, To MM, Nguyen TB, Nguyen DC, Gautret P, Hoang VT. Clinical and Laboratory Characteristics of Kawasaki Disease and COVID-19-Related Multisystem Inflammatory Syndrome in Children. J Korean Med Sci. 2023, 38, e410. [CrossRef]
- Cattalini M, Della Paolera S, Zunica F, et al. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatr Rheumatol Online J. 2021, 19, 29.
- Bar-Meir M, Guri A, Godfrey ME, et al. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep. 2021, 11, 13840. [CrossRef]
- Yavuz L, AlHamdani S, Alasrawi S, et al. Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) in a Middle Eastern patient cohort. Pediatr Rheumatol Online J. 2023, 21, 64. [CrossRef]
- Cem E, Böncüoğlu E, Kıymet E, Şahinkaya Ş, Çelebi MY, Gülderen M, Kaçar P, Kara AA, Aydın A, Murat M, Yılmazer MM, Bayram N, Devrim İ. Which Findings Make multisystem Inflammatory Syndrome in Children Different from the Pre-Pandemic Kawasaki Disease? Pediatric Cardiology. 2023; 44, 424-432.
- Ünlü AM, Holm M, Hafstrøm TK, Glerup M, Bjerre J, Herlin T. Changes in Kawasaki disease incidence and phenotype during the COVID-19 pandemic. Dan Med J. 2023, 70, A10220600.
- Iio K, Matsubara K, Miyakoshi C, Ota K, Yamaoka R, Eguchi J, Matsumura O, Okutani T, Ueda I, Nishiyama M. Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan. BMJ Paediatrics Open. 2021, 5, e001034. [CrossRef]
- Şener, S, Batu, ED, Akca ÜK, Atalay E, Cüceoğlu MK, Balık Z, Başaran Ö, Karagöz T, Özsürekçi Y, Bilginer Y, Özen S. Differentiating Multisystem Inflammatory Syndrome in Children from Kawasaki Disease During the Pandemic. Turk Arch Pediatr. 2024, 59, 150–156. [CrossRef]
- Sarı E, Erdede Ö. Comparison of Eosinophil Counts in Inflammatory Conditions: Multisystem Inflammatory Syndrome in Children, Kawasaki Disease, and Infectious Mononucleosis. Children (Bazel). 2024, 11, 204. [CrossRef]
- Ciftdoğan DY, Keles YE, Cetin BS et all. COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group. European Journal of Pediatrics. 2022, 181, 2031–2043. [CrossRef]
- Mehrban S, Tahghighi F, Moghadam EA, Ziaee V. Multisystem inflammatory syndrome in children and Kawasaki disease; comparison of their clinical findings and one-year follow-up—a cross-sectional study. Ital J Pediatr. 2023, 49, 90. [CrossRef]
- Alkan F, Bircan O, Bal A, Bayturan S, Zengin N, Coskun S. Comparison of early characteristics of multisystemic inflammatory syndrome and Kawasaki disease in children and the course of Kawasaki disease in the pandemic. BMC Pediatrics. 2024, 24, 485. [CrossRef]
- Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020, 183, 968–981. [CrossRef]
- Matsubara D, Kauffman HL, Wang Y, et al. Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States. J Am Coll Cardiol. 2020, 76, 1947–61. [CrossRef]
- Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr. 2021, 175, 837–845. [CrossRef]
- Fridman DM, Tsoukas P, Jeewa A, Yeung RSM, Gamulka BD, McCrindle BW. Differentiation of COVID-19 Associated Multisystem Inflammatory Syndrome From Kawasaki Disease With the Use of Cardiac Biomarkers. Canadian Journal of Cardiology. 2023, 39, 815–823. [CrossRef]
- Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr. 2018, 44, 103. [CrossRef]
- Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020, 79, 999–1006.
- Kaya Akca U, Atalay E, Cuceoglu MK, et al. Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases. Rheumatol Int. 2022, 42, 51–57. [CrossRef]
|
MIS-C |
Individuals aged <21 years presenting with fever; laboratory evidence of inflammation; clinical evidence of severe illness requiring hospitalization; multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or gastrointestinal);
|
|
Classical KD |
Patients with persistent fever for ≥5 days (or until the day of intravenous immunoglobulin administration, if administered before day 5 of fever) and exhibiting at least four of the following five clinical signs:
|
| Atypical KD | Patients whose disease did not meet the abovementioned KD criteria but who had a fever and coronary artery abnormalities. The diagnostic criteria were as follows: fever persisting for ≥5 days and meeting two to three diagnostic criteria or infants presenting with idiopathic fever for ≥7 days.
|
| MIS-C Patients (n = 39) |
KD Patients (n = 17) |
p | |
| Age, months Median (min-max) IQR (P 25-P 75) |
138 (7-214) (97-182) |
36 (18-48) (32-42) |
<0.001 |
| Sex, n (%) Male Female |
33 (84.6) 6 (15.3) |
10 (58.8) 7 (41.1) |
0,992 |
| Clinical symptoms | |||
| Days of fever Median (min-max) IQR (P 25-P 75) |
3 (1-7) (3-5) |
6 (5-7) (5-6) |
<0.001 |
| Rash, n (%) | 2 (5.1) | 12 (70.5) | <0.001 |
| Oral mucosal changes n (%) |
4 (10.2) | 14 (82.3) | <0.001 |
| Bilateral conjunctival injection, n (%) | 6 (15.3) | 12 (70.5) | <0.001 |
| Erythema and edema of extremities, n (%) | 0 (0) | 6 (35.2) | <0.001 |
| Cervical lymphadenopathy, n (%) | 6 (15.3) | 15 (88.2) | <0.001 |
| Acute gastrointestinal symptoms, n (%) | 22 (66.6) | 2 (11.7) | <0,001 |
| Acute respiratory symptoms, n (%) | 17 (43.5) | 0 (0) | 0.001 |
| Hypotension, n (%) | 11 (28.2) | 0 (0) | 0.024 |
| Laboratory findings Median (min-max) IQR (P 25-P 75) |
MIS-C Patients |
KD Patients |
p |
| White blood cell count (×103/μL) | 7600 (500-31000) (4800-11300) |
15000 (12200-17600) (14400-16000) |
<0.001 |
| Hemoglobin, g/dL | 10,4 (7-15,4) (9,3-12,9) |
11 (10-12) (10,5-11,3) |
0.568 |
| Neutrophil (%) | 85 (26-95) (75-90) |
57 (43-75) (49-65) |
<0.001 |
| Platelet count (×103/uL) | 180 (7-446) (99000-263000) |
290 (220-400) (270000-360000) |
<0.001 |
| C-reactive protein, mg/dL (<0.5) | 113 (1,5-329) (18-190) |
14 (9-35) (12-17) |
<0.001 |
| Erythrocyte sedimentation rate, mm/h (<20) | 34 (4-114) (23-68) |
40 (24-48) (35-43) |
0.859 |
| Procalcitonin ng/ml (<0,05) | 3,18 (0,01-168) (0,47-16) |
0,02 (0,01-0,05) (0,01-0,03) |
<0.001 |
| Interleukin-6, pg/mL (<5.9) | 100 (2,48-2000) (12-280) |
28 (6-45) (14-38) |
0.014 |
| Alanine aminotransferase, IU/L (<39) | 22 (5-381) (14-38) |
60 (40-84) (55-67) |
<0.001 |
| Albumin g/L (38-54) | 31 (11,1-48) (28-39) |
30 (20-42) (24-35) |
0.208 |
| Ferritin, ng/ml (<207) | 454 (27-3381) (198-1143) |
80 (20-145) (45-120) |
<0.001 |
| Fibrinogen mg/L (<400) | 485 (176-724) (408-585) |
280 (210-550) (230-400) |
<0.001 |
| D-Dimer, mg/L (<0.5) | 3.4 (0.34-35) (1,8-5,19) |
0.8 (0.2-1.4) (0,5-1) |
<0.001 |
| Troponin I, picogram/ml (<0.14) | 60 (0-106695) (22-146) |
10 (3-18) (6-12) |
0.001 |
| NT-proBNP pg/mL (<100) |
980 (10-35000) (300-2010) |
45 (12-90) (34-75) |
<0.001 |
| Echocardiographic findings, n (%) | MIS-C Patients | KD Patients | p |
| Coronary dilation/aneurysm | 5 (12.8) | 0 (0) | 0.309 |
| Decreased left ventricular function | 10(25.6) | 0 (0) | 0.023 |
| Myocarditis | 7 (17.9) | 0 (0) | 0.088 |
| Pericarditis | 3 (7.69) | 0 (0) | 0.546 |
| Treatments, n (%) | |||
| Intravenous immunoglobulin | 33 (84.6) | 17 (100) | 0.087 |
| Corticosteroids | 30 (76.9) | 0 (0) | <0.001 |
| Subcutaneous enoxaparin | 9 (23) | 0 (0) | 0.045 |
| Anakinra | 3 (7.69) | 0 (0) | 0.546 |
| Therapeutic plasma exchange | 22 (56.4) | 0 (0) | <0.001 |
| Invasive mechanical ventilatory support | 7 (17.9) | 0 (0) | 0.088 |
| Hospitalization duration, days, median (min-max) | 6 (1-12) | 4 (2-6) | 0.023 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
